Diageo : bounces on positive forecast
Jean-Christophe Rolland September 28, 2020 5:51 PM
The company said that 1H 2021 outlook has improved.
The liquor maker jumps this morning after saying that "US business is performing strongly and ahead of expectations." The company added that it continues "to expect sequential improvement in organic net sales and operating profit compared to the second half of fiscal 20."
From a chartist point of view, the stock opened with a bullish gap and trades above its 50-day moving average while the RSI is now in bullish territory. As long as 2449 is not broken (September 25th low) is not broken, a continuation of the rebound would be expected towards 2900 at first.
Source : TradingVIEW, Gain Capital
From time to time, GAIN Capital Australia Pty Ltd (“we”, “our”) website may contain links to other sites and/or resources provided by third parties. These links and/or resources are provided for your information only and we have no control over the contents of those materials, and in no way endorse their content. Any analysis, opinion, commentary or research-based material on our website is for information and educational purposes only and is not, in any circumstances, intended to be an offer, recommendation or solicitation to buy or sell. You should always seek independent advice as to your suitability to speculate in any related markets and your ability to assume the associated risks, if you are at all unsure. No representation or warranty is made, express or implied, that the materials on our website are complete or accurate. We are not under any obligation to update any such material.
As such, we (and/or our associated companies) will not be responsible or liable for any loss or damage incurred by you or any third party arising out of, or in connection with, any use of the information on our website (other than with regards to any duty or liability that we are unable to limit or exclude by law or under the applicable regulatory system) and any such liability is hereby expressly disclaimed.